The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer

Journal of Molecular Diagnostics

Volumn 12, Issue 5, 2010, Pages 705-711

  Mancini, Irene ^a   Santucci, Claudio ^a   Sestini, Roberta ^a   Simi, Lisa ^a   Pratesi, Nicola ^a   Cianchi, Fabio ^a   Valanzano, Rosa ^a   Pinzani, Pamela ^a   Orlando, Claudio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN;

ADULT; AGED; ARTICLE; COAMPLIFICATION AT LOWER DENATURATION TEMPERATURE POLYMERASE CHAIN REACTION; COLORECTAL CANCER; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; WILD TYPE;

EID: 77956792325     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2010.100018     Document Type: Article

References (40)

1. Sawyers CL: The cancer biomarker problem. Nature 2008, 452:548-552
2. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009, 9:489-499
3. Chau I, Cunningham D: Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 2009, 100:1704-1719
4. Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di Leo A: Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res 2009, 11:205-216
5. John T, Liu G, Tsao MS: Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 2009, 28(Suppl1):S14-S23
6. Febbo PG: Genomic approaches to outcome prediction in prostate cancer. Cancer 2009, 115:3046-3057
7. Pai SI, Westra WH: Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol 2009, 4:49-70
8. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG: KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 2009, 27:1130-1136
9. Raymond E, Faivre S, Armand JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000, 60:15-23
10. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-6565 (Pubitemid 32197693)
11. Galizia G, Lieto E, De Vita F, Orditura M, Castellano P, Troiani T, Imperatore V, Ciardiello F: Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007, 26:3654-3660 (Pubitemid 46842715)
12. Bardelli A, Siena S: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010, 28:1254-1261
13. Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ: Working Group on Economic Analysis of the National Cancer Institute of Canada Clinical Trials Group Australasian Gastrointestinal Interest Group. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO 17 Trial. J Natl Cancer Inst 2009, 101:1182-1192
14. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A: Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 2009, 205:858-862
15. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27:2091-2096
16. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R: B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23:6292-6298
17. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009, 101:465-472
18. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K, Chapman P: Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009, 27:15s (abstr 9000)
19. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P: KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS Trial. J Clin Oncol 2009, 27:5931-5937
20. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, CatalanoV, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009, 101:715-721
21. Meriggi F, Di Biasi B, Abeni C, Zaniboni A: Anti-Egfr Therapy in Colorectal Cancer: how to Choose the Right Patient. Curr Drug Targets 2009, 10:1033-1040
22. Tindall EA, Petersen DC, Woodbridge P, Schipany K, Hayes VM: Assessing high-resolution melt curve analysis for accurate detection of gene variants in complex DNA fragments. Hum Mutat 2009, 30:876-883
23. Wittwer CT: High-resolution DNA melting analysis: advancements and limitations. Hum Mutat 2009, 30:857-859
24. Vossen RH, Aten E, Roos A, den Dunnen JT: High-resolution melting analysis (HRMA): more than just sequence variant screening. Hum Mutat 2009, 30:860-866
25. Taylor CF: Mutation scanning using high-resolution melting. Biochem Soc Trans 2009, 37:433-437
26. Ronaghi M, Shokralla S, Gharizadeh B: Pyrosequencing for discovery and analysis of DNA sequence variations. Pharmacogenomics 2007, 8:1437-1441
27. Langaee T, Ronaghi M: Genetic variation analyses by Pyrosequencing. Mutat Res 2005, 573:96-102
28. Morlan J, Baker J, Sinicropi D: Mutation detection by real-time PCR: a simple, robust and highly selective method. PLoS One 2009, 4:e4584
29. Tol J, Dijkstra JR, Vink-Börger ME, Nagtegaal ID, Punt CJ, van Krieken JH, Ligtenberg MJ: High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med 2009, doi: 10.1111/j.1582-4934.2009.00788x
30. Orum H: PCR clamping. Curr Issues Mol Biol 2000, 2:27-30. Review.
31. Zuo Z, Chen SS, Chandra PK, Galbincea JM, Soape M, Doan S, Barkoh BA, Koeppen H, Medeiros LJ, Luthra R: Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol 2009, 22:1023-1031
32. Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM: Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 2008, 14:579-584
33. Li J, Milbury CA, Li C, Makrigiorgos GM: Two-round coamplification at lower denaturation temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinoma. Hum Mutat 2009, 30:1583-1590
34. Delaney D, Diss TC, Presneau N, Hing S, Berisha F, Idowu BD, O'Donnell P, Skinner JA, Tirabosco R, Flanagan AM: GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma. Mod Pathol 2009, 22:718-724
35. Reed GH, Wittwer CT: Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem 2004, 50:1748-1754
36. Graham R, Liew M, Meadows C, Lyon E, Wittwer CT: Distinguishing different DNA heterozygotes by high-resolution melting. Clin Chem 2005, 51:1295-1298
37. Milbury CA, Li J, Makrigiorgos GM: COLD-PCR-enhanced high-resolution melting enables rapid and selective identification of low-level unknown mutations. Clin Chem 2009, 55:2130-2143
38. Jass JR, Sobin LH: International Histological Classification of Tumors. 2nd Ed. Histological Typing of Intestinal Tumors. Berlin, Germany: Springer-Verlag; 1989
39. O'Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer ed 4 staging. J Natl Cancer Inst 2004, 6:1420-1425 (Pubitemid 39429665)
40. Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R, Nobili S, Mini E, Pazzagli M, Orlando C: High-resolution melting analysis for rapid detection of KRAS. BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 2008, 130:247-253